Following on from information provided to NICE by the company in October 2021 the appraisal of Retifanlimab for treating anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3815 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 December 2022 | Discontinued. Following on from information provided to NICE by the company in October 2021 the appraisal of Retifanlimab for treating anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 29 October 2021 | Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of retifanlimab for treating anal canal squamous cell carcinoma after platinum-based chemotherapy. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 01 October 2021 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid February 2022. |
| 02 June 2021 - 30 June 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 28 October 2019 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual